BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2022 11:52:44 AM | Browse: 227 | Download: 452
 |
Received |
|
2021-11-09 16:20 |
|
Peer-Review Started |
|
2021-11-09 16:21 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-27 08:36 |
|
Revised |
|
2022-01-24 05:00 |
|
Second Decision |
|
2022-08-12 03:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-08-17 22:02 |
|
Articles in Press |
|
2022-08-17 22:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-07-24 02:01 |
|
Typeset the Manuscript |
|
2022-09-01 09:15 |
|
Publish the Manuscript Online |
|
2022-09-16 11:52 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shu-Guang Zhu, Hai-Bo Li, Tian-Xing Dai, Hua Li and Guo-Ying Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The National 13th Five-Year Science and Technology Plan Major Projects of China |
2017ZX10203205-006-001; 2017ZX10203205-001-003 |
|
| Corresponding Author |
Guo-Ying Wang, MD, PhD, Associate Professor, Chief Doctor, Director, Surgeon, Department of Hepatic Surgery and Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, , TIANHE Road No.600, Guangzhou 510630, Guangdong Province, China. wanggy3@126.com |
| Key Words |
Intrahepatic cholangiocarcinoma; Lymph node metastasis; Neoadjuvant therapy; Immunotherapy; Chemotherapy; Surgical resection; Case report |
| Core Tip |
At present, the objective remission rate of intrahepatic cholangiocarcinoma (ICC) in the treatment of advanced hepatocellular carcinoma (HCC) patients is approximately 20%. The development of more sensitive and efficient predictive methods will improve the benefits of ICC therapy in potential patients with advanced HCC and benefit patients who are suitable for ICC therapy. This will hopefully open up a new prospect of immunotherapy for liver tumors. Immunotherapy may be a potential treatment option for ICC. |
| Publish Date |
2022-09-16 11:52 |
| Citation |
Zhu SG, Li HB, Dai TX, Li H, Wang GY. Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report. World J Clin Cases 2022; 10(27): 9743-9749 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i27/9743.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i27.9743 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
